On this basis, and since low HSP90 activity induces apoptosis in lung cancer [56,57], our results suggest that this cell death pathway is a key process during the pharmacological inhibition of HSP90 in lung adenocarcinoma, regardless of the molecular subtype and inhibitor used. This evidence concerns the gene HSP90AA1 and lung carcinoma.